vs
Calumet, Inc.（CLMT）与爱德华生命科学（EW）财务数据对比。点击上方公司名可切换其他公司
爱德华生命科学的季度营收约是Calumet, Inc.的1.6倍（$1.6B vs $1.0B），爱德华生命科学净利率更高（23.1% vs -3.6%，领先26.7%）
Calumet是总部位于美国的特种产品企业，专注于生产和分销高价值碳氢化合物与特种化学品，产品覆盖特种油、润滑剂、蜡制品及可再生燃料解决方案，服务北美及全球的工业、消费、交通等下游领域。
爱德华生命科学是总部位于美国加利福尼亚州尔湾的医疗科技企业，专注于人工心脏瓣膜及血流动力学监测领域，其研发的Sapien经导管主动脉心脏瓣膜采用牛组织材质，搭配球囊扩张式钴铬合金支架，可通过导管完成植入。
CLMT vs EW — 直观对比
营收规模更大
EW
是对方的1.6倍
$1.0B
净利率更高
EW
高出26.7%
-3.6%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $1.6B |
| 净利润 | $-37.3M | $380.7M |
| 毛利率 | -0.3% | 78.0% |
| 营业利润率 | -6.2% | 1.8% |
| 净利率 | -3.6% | 23.1% |
| 营收同比 | — | 16.7% |
| 净利润同比 | — | 6.8% |
| 每股收益（稀释后） | $-0.43 | $0.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLMTEW
| Q1 26 | — | $1.6B | ||
| Q4 25 | $1.0B | $1.6B | ||
| Q3 25 | $1.1B | $1.6B | ||
| Q2 25 | $1.0B | $1.5B | ||
| Q1 25 | $993.9M | $1.4B | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | $1.1B | $1.4B | ||
| Q2 24 | $1.1B | $1.4B |
净利润CLMTEW
| Q1 26 | — | $380.7M | ||
| Q4 25 | $-37.3M | $91.2M | ||
| Q3 25 | $313.4M | $291.1M | ||
| Q2 25 | $-147.9M | $333.2M | ||
| Q1 25 | $-162.0M | $358.0M | ||
| Q4 24 | — | $385.6M | ||
| Q3 24 | $-100.6M | $3.1B | ||
| Q2 24 | $-39.1M | $366.3M |
毛利率CLMTEW
| Q1 26 | — | 78.0% | ||
| Q4 25 | -0.3% | 78.1% | ||
| Q3 25 | 34.7% | 77.8% | ||
| Q2 25 | -4.2% | 77.5% | ||
| Q1 25 | -8.2% | 78.7% | ||
| Q4 24 | — | 78.9% | ||
| Q3 24 | 0.4% | 80.6% | ||
| Q2 24 | 5.6% | 79.9% |
营业利润率CLMTEW
| Q1 26 | — | 1.8% | ||
| Q4 25 | -6.2% | 9.6% | ||
| Q3 25 | 30.0% | 19.8% | ||
| Q2 25 | -9.8% | 26.8% | ||
| Q1 25 | -4.9% | 27.9% | ||
| Q4 24 | — | 22.6% | ||
| Q3 24 | -5.2% | 25.9% | ||
| Q2 24 | 0.5% | 26.8% |
净利率CLMTEW
| Q1 26 | — | 23.1% | ||
| Q4 25 | -3.6% | 5.8% | ||
| Q3 25 | 29.1% | 18.7% | ||
| Q2 25 | -14.4% | 21.7% | ||
| Q1 25 | -16.3% | 25.3% | ||
| Q4 24 | — | 27.8% | ||
| Q3 24 | -9.1% | 226.7% | ||
| Q2 24 | -3.4% | 26.7% |
每股收益（稀释后）CLMTEW
| Q1 26 | — | $0.66 | ||
| Q4 25 | $-0.43 | $0.16 | ||
| Q3 25 | $3.61 | $0.50 | ||
| Q2 25 | $-1.70 | $0.56 | ||
| Q1 25 | $-1.87 | $0.61 | ||
| Q4 24 | — | $0.65 | ||
| Q3 24 | $-1.18 | $5.13 | ||
| Q2 24 | $-0.48 | $0.61 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $125.1M | — |
| 总债务越低越好 | $2.1B | — |
| 股东权益账面价值 | $-732.7M | — |
| 总资产 | $2.7B | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CLMTEW
| Q1 26 | — | — | ||
| Q4 25 | $125.1M | $4.2B | ||
| Q3 25 | $94.6M | $3.8B | ||
| Q2 25 | $110.6M | $4.1B | ||
| Q1 25 | $123.4M | $3.9B | ||
| Q4 24 | — | $4.0B | ||
| Q3 24 | $34.6M | $4.4B | ||
| Q2 24 | $7.0M | $2.0B |
总债务CLMTEW
| Q1 26 | — | — | ||
| Q4 25 | $2.1B | — | ||
| Q3 25 | $2.1B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.3B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.7B | — | ||
| Q2 24 | — | — |
股东权益CLMTEW
| Q1 26 | — | — | ||
| Q4 25 | $-732.7M | $10.3B | ||
| Q3 25 | $-695.3M | $10.2B | ||
| Q2 25 | $-1.0B | $10.5B | ||
| Q1 25 | $-862.3M | $10.1B | ||
| Q4 24 | — | $10.0B | ||
| Q3 24 | $-672.2M | $9.5B | ||
| Q2 24 | $-566.4M | $7.4B |
总资产CLMTEW
| Q1 26 | — | — | ||
| Q4 25 | $2.7B | $13.7B | ||
| Q3 25 | $2.7B | $13.3B | ||
| Q2 25 | $2.8B | $13.5B | ||
| Q1 25 | $2.8B | $13.0B | ||
| Q4 24 | — | $13.1B | ||
| Q3 24 | $2.6B | $13.0B | ||
| Q2 24 | $100 | $10.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $116.5M | — |
| 自由现金流经营现金流 - 资本支出 | $103.8M | — |
| 自由现金流率自由现金流/营收 | 10.0% | — |
| 资本支出强度资本支出/营收 | 1.2% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $56.6M | — |
8季度趋势，按日历期对齐
经营现金流CLMTEW
| Q1 26 | — | — | ||
| Q4 25 | $116.5M | $450.9M | ||
| Q3 25 | $23.5M | $573.7M | ||
| Q2 25 | $-1.8M | $290.2M | ||
| Q1 25 | $-29.3M | $280.4M | ||
| Q4 24 | — | $-127.5M | ||
| Q3 24 | $-15.5M | $351.8M | ||
| Q2 24 | — | $371.5M |
自由现金流CLMTEW
| Q1 26 | — | — | ||
| Q4 25 | $103.8M | $353.5M | ||
| Q3 25 | $15.1M | $516.2M | ||
| Q2 25 | $-15.4M | $240.9M | ||
| Q1 25 | $-46.9M | $224.4M | ||
| Q4 24 | — | $-177.3M | ||
| Q3 24 | $-32.2M | $299.9M | ||
| Q2 24 | — | $286.1M |
自由现金流率CLMTEW
| Q1 26 | — | — | ||
| Q4 25 | 10.0% | 22.5% | ||
| Q3 25 | 1.4% | 33.2% | ||
| Q2 25 | -1.5% | 15.7% | ||
| Q1 25 | -4.7% | 15.9% | ||
| Q4 24 | — | -12.8% | ||
| Q3 24 | -2.9% | 22.1% | ||
| Q2 24 | — | 20.9% |
资本支出强度CLMTEW
| Q1 26 | — | — | ||
| Q4 25 | 1.2% | 6.2% | ||
| Q3 25 | 0.8% | 3.7% | ||
| Q2 25 | 1.3% | 3.2% | ||
| Q1 25 | 1.8% | 4.0% | ||
| Q4 24 | — | 3.6% | ||
| Q3 24 | 1.5% | 3.8% | ||
| Q2 24 | 2.2% | 6.2% |
现金转化率CLMTEW
| Q1 26 | — | — | ||
| Q4 25 | — | 4.94× | ||
| Q3 25 | 0.07× | 1.97× | ||
| Q2 25 | — | 0.87× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | -0.33× | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 1.01× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLMT
| Specialty Products And Solutions | $675.9M | 65% |
| Montana Renewables | $294.2M | 28% |
| Performance Brands | $68.5M | 7% |
EW
暂无分部数据
